|Articles|April 14, 2004
FDA says Aldara "approvable" for superficial basal cell carcinoma Tx
Source: www.pharmalive.com 3M has received an ?approvable? letter from the FDA in response to its supplemental new drug application on Aldara (imiquimod cream), 5 percent, for treatment of superficial basal cell carcinoma, a common form of non-melanoma skin cancer.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Next-Generation IL-4Rα Targeting and Potential Dermatologic Implications
2
Graham Heap, MBBS, PhD, Discusses Positive Phase 3 Results for Zasocitinib
3
Off-Label Case Series: Topical Roflumilast for Mild HS
4
Auricular Acupuncture for Facial Rejuvenation: Results from a Large Real-World Clinical Series
5














